PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
J. Burger,
M. Sivina,
E. Kim,
G. Issa,
W. Wierda,
N. Jain,
P. Thompson,
A. Ferrajoli
Affiliations
J. Burger
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
M. Sivina
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
E. Kim
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
G. Issa
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
W. Wierda
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
N. Jain
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
P. Thompson
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
A. Ferrajoli
1 Leukemia, MD Anderson Cancer Center, Houston, United States of America
